Literature DB >> 17160794

[Expenditures for members of a health insurance company suffering from alcoholism - a payer's view].

Klaus Stamm1, Silke Merkel, Karl Mann, Hans Joachim Salize.   

Abstract

AIM: In this study, expenditures of a health insurance company for alcoholics are calculated and analysed.
METHOD: Data are derived from the company's records. To participate in this study, subjects had to have a clearly alcohol-related diagnosis during a stay in hospital or a time-off work in 2001 (index-year). 127 Persons were identified according to these criteria. The sample was divided into two groups, those with an alcohol-related diagnosis only in 2001 (Group 1) and those with an alcohol-related diagnosis in at least one other year (Group 2, chronic condition). Expenditures are calculated, cost figures are compared with the health insurance company's average means. For Group 1, the course of costs is examined. Also, cost-predictors are identified.
RESULTS: The results show increased costs for alcoholics for all sectors included. Further analyses revealed higher expenditures for persons with a chronic condition (Group 2) and older age. The course of costs for Group 1 shows that expenditures here are clearly increased in the index-year, but not in the other years.
CONCLUSIONS: A recurrent diagnosis of alcoholism leads to high costs for health insurance companies. Investments in effective prevention and treatment strategies are recommended to reduce the financial burden.

Entities:  

Mesh:

Year:  2006        PMID: 17160794     DOI: 10.1055/s-2006-940062

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  1 in total

1.  Outpatient Psychotherapy Reduces Health-Care Costs: A Study of 22,294 Insurants over 5 Years.

Authors:  Uwe Altmann; Anna Zimmermann; Helmut A Kirchmann; Dietmar Kramer; Andrea Fembacher; Ellen Bruckmayer; Irmgard Pfaffinger; Fritz von Heymann; Emma Auch; Rolf Steyer; Bernhard M Strauss
Journal:  Front Psychiatry       Date:  2016-06-13       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.